insulin aspart
Drug ingredientThis chemical is an active pharmaceutical ingredient used in FDA-regulated drugs.
Where It Comes From
10 FDA-registered drug labelers
A-S Medication Solutions
Amphastar Nanjing Pharmaceuticals, Inc.
Biocon Biologics Inc.
Hefei Xinzhu Biological Technology Co., Ltd.
Novo Nordisk
Novo Nordisk A/S
Novo Nordisk Pharma, Inc.
REMEDYREPACK INC.
Sanofi-Aventis Deutschland GmbH
Sanofi-Aventis U.S. LLC
Why It Matters
Sectors
Health
Downstream Uses
Appears in 8 drug and cosmetic product listings (FDA).
- •NovoLog Mix 70/30
- •Insulin Aspart
- •Insulin Aspart Protamine and Insulin Aspart Mix 70/30
- •Novolog
- •Fiasp
- •Kirsty
- •Merilog
- •.Insulin Aspart Protamine and Insulin Aspart
FDA Shortage Status
Whether any manufacturer currently reports this drug as in shortage on the FDA Drug Shortages database. "Active Shortage" means at least one presentation has status "current."
No Shortage
Shortage History
Each row is a separate manufacturer's FDA shortage filing — not a timeline for the drug as a whole. Multiple "current" entries are normal: each manufacturer/NDC files independently. Status reflects the manufacturer's report; reason describes their supply situation (Available, Unavailable, or to be discontinued).
to be discontinued
Insulin Aspart Injection
07/21/2025to be discontinued
Insulin Aspart Protamine and Insulin Aspart Mix 70/30 Injectable Suspension
07/21/2025Chemical Identity
CAS116094-23-6
PubChem CID16132418
DTXSIDDTXSID10151274
FormulaC256H387N65O79S6
Mol. Weight5832 g/mol
SMILESCCC(C)C(C(=O)NC(C(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(CCC(=O)N)C(=O)NC(CS)C(=O)NC(CS)C(=O)NC(C(C)O)C(=O)NC(CO)C(=O)NC(C(C)CC)C(=O)NC(CS)C(=O)NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC1=CC=C(C=C1)O)C(=O)NC(CCC(=O)N)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(CC(=O)N)C(=O)NC(CC2=CC=C(C=C2)O)C(=O)NC(CS)C(=O)NC(CC(=O)N)C(=O)O)NC(=O)CN.CC(C)CC(C(=O)NC(CC1=CC=C(C=C1)O)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CS)C(=O)NCC(=O)NC(CCC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CC2=CC=CC=C2)C(=O)NC(CC3=CC=CC=C3)C(=O)NC(CC4=CC=C(C=C4)O)C(=O)NC(C(C)O)C(=O)NC(CC(=O)O)C(=O)NC(CCCCN)C(=O)NC(C(C)O)C(=O)O)NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC5=CN=CN5)NC(=O)C(CO)NC(=O)CNC(=O)C(CS)NC(=O)C(CC(C)C)NC(=O)C(CC6=CN=CN6)NC(=O)C(CCC(=O)N)NC(=O)C(CC(=O)N)NC(=O)C(C(C)C)NC(=O)C(CC7=CC=CC=C7)N
Data Sources
161324182026-04-07
https://pubchem.ncbi.nlm.nih.gov/rest/pug/compound/name/insulin aspart/cids/JSON
Archive: data/sources/pubchem_name/insulin aspart.json
CAS 116094-23-62026-04-25
https://open.fda.gov/data/ndc/
Archive: data/sources/fda/ndc/ndc.json
CAS 116094-23-62026-06-13
https://api.fda.gov/drug/shortages.json
Archive: data/sources/fda/shortages/shortages.json